Skip to Content

Exact Sciences Corp EXAS Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close 66.85
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style Mid Growth
  • Day Range 66.40  –  70.42
  • Year Range 29.27  –  100.77
  • Market Cap 12.0775 Bil
  • Volume / Avg 2.4 Mil /  1.4 Mil
  • Price / Sales 5.18
  • Price / Book 3.95
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis EXAS

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Exact Sciences' Cologuard Continues to Grow as an Alternative to Colonoscopy

Julie Utterback Senior Equity Analyst

Business Strategy and Outlook

| Julie Utterback |

Exact Sciences has a three-pronged approach to cancer testing: non-invasive Cologuard is likely to continue gaining share of colorectal cancer screening, and ongoing development of both early screening and minimum residual disease, or MRD, testing gives Exact exposure to the nascent liquid biopsy market. Exact is attempting to position itself as a winner regardless of whether liquid biopsy takes off, with Cologuard likely to remain a decent alternative to colonoscopy over the near term, while the firm’s pan-cancer and single-cancer liquid biopsy tests could offset Cologuard share loss in a scenario where liquid biopsy rapidly gains share.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EXAS

Company Profile EXAS

Business Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.

5505 Endeavor Lane
Madison, WI, 53719
Industry Diagnostics & Research
Employees 6,400

Related Articles EXAS

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of EXAS’s competitive advantage.

Exact Sciences Corp


Illumina Inc


Myriad Genetics Inc


Guardant Health Inc

−$2.68 (3.85%) −$0.89 (0.67%) −$0.16 (0.95%) −$0.18 (0.69%)
Market Cap
12.08 Bil20.97 Bil1.36 Bil3.05 Bil
Diagnostics & Research Diagnostics & Research Diagnostics & Research Diagnostics & Research

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Exact Sciences Corp Stock

No. EXAS does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

EXAS’s market cap is 12.08 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

EXAS’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

EXAS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare EXAS’s historical performance against its industry peers and the overall market.